Sander W Tas
Overview
Explore the profile of Sander W Tas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
1998
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keijser J, Stalman E, Wieske L, Steenhuis M, van Dam K, Kummer L, et al.
EBioMedicine
. 2025 Feb;
113:105620.
PMID: 40010153
Background: Repeated antigen exposure can result in a shifting antibody repertoire. The mechanisms by which this occurs and consequences for cross-variant protection against evolving pathogens remain incompletely understood, particularly in...
2.
Frazzei G, Landewe R, Wagenaar C, van de Stadt L, van Schaardenburg D, Tas S, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39956700
Objectives: The aim of this study was to predict rheumatoid arthritis (RA) development in a cohort of at-risk individuals with arthralgia positive for anti-citrullinated protein antibodies (ACPA) and/or rheumatoid factor...
3.
Geertsema-Hoeve B, van Laar J, Raaphorst J, Tas S, Welsing P, Goekoop R, et al.
BMJ Open
. 2025 Feb;
15(2):e089827.
PMID: 39915014
Introduction: Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) faces significant challenges, including small patient populations, complex clinical trial design and difficulties in patient recruitment. Patients with Behçet's...
4.
Khodadust F, Philippon E, Steinz M, van Hamburg J, Van Meerloo J, van Beijnum J, et al.
Cells
. 2025 Jan;
14(2).
PMID: 39851530
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation leading to joint damage and systemic complications. Angiogenesis promotes inflammation and contributes to RA progression. This study evaluated potential...
5.
Frazzei G, Cramer S, Landewe R, Maijer K, Gerlag D, Tak P, et al.
RMD Open
. 2024 Oct;
10(4).
PMID: 39424405
Objectives: Early treatment of individuals at risk of developing rheumatoid arthritis (RA-risk) in the preclinical phase has the potential to positively impact both patients and society by preventing disease onset...
6.
Kummer L, Blanco L, Kreher C, Bos A, Kuijper L, Verstegen N, et al.
RMD Open
. 2024 Oct;
10(4).
PMID: 39375177
Objectives: Methotrexate (MTX) is one of the most commonly used medications to treat rheumatoid arthritis (RA). However, the effect of MTX treatment on cellular immune responses remains incompletely understood. This...
7.
Ochoa S, Hsu A, Oler A, Kumar D, Chauss D, van Hamburg J, et al.
Sci Transl Med
. 2024 Sep;
16(765):eadk0845.
PMID: 39292801
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a life-threatening monogenic autoimmune disorder primarily caused by biallelic deleterious variants in the autoimmune regulator () gene. We prospectively evaluated 104 patients with clinically diagnosed...
8.
Bergkamp S, Bergkamp N, Wahadat M, Gruppen M, Nassar-Sheikh Rashid A, Tas S, et al.
Lupus Sci Med
. 2024 Sep;
11(2).
PMID: 39242108
Objectives: In childhood-onset SLE (cSLE), patients have an increased risk of premature atherosclerosis. The pathophysiological mechanisms for this premature atherosclerosis are not yet completely understood, but besides traditional risk factors,...
9.
de Wit M, Aouad K, Elhai M, Benavent D, Bertheussen H, Blackburn S, et al.
Ann Rheum Dis
. 2024 Jun;
83(11):1443-1453.
PMID: 38876509
Background: Since the publication of the 2011 European Alliance of Associations for Rheumatology (EULAR) recommendations for patient research partner (PRP) involvement in rheumatology research, the role of PRPs has evolved...
10.
Curtis J, Wollenhaupt J, Tas S, Chatzidionysiou K, Wang L, Roberts K, et al.
Rheumatol Adv Pract
. 2024 Jun;
8(2):rkae063.
PMID: 38854417
Objectives: To examine determinants of tofacitinib discontinuation due to voluntary (i.e. patient-driven) or involuntary reasons (i.e. protocol mandated) in long-term extension (LTE) studies of patients with RA to inform clinical...